Filings

6 documents · 20 matches

1. APUS Apimeds Pharmaceuticals US, Inc. 10-K 2026-05-04

   Item 9A. Controls and Procedures

   material weakness in internal controls is a deficiency in internal control, or combination of control deficiencies, that adversely affects our ability
   7 matches in this document Show context Copy citation

2. APUS Apimeds Pharmaceuticals US, Inc. 10-Q 2025-05-20

   Item 4. Controls and Procedures

   material weakness in internal controls is a deficiency in internal control, or combination of control deficiencies, that adversely affects our ability
   3 matches in this document Show context Copy citation

3. APUS Apimeds Pharmaceuticals US, Inc. 10-Q 2026-05-26

   Item 4. Controls and Procedures

   material weakness in internal controls is a deficiency in internal control, or combination of control deficiencies, that adversely affects our ability
   3 matches in this document Show context Copy citation

4. APUS Apimeds Pharmaceuticals US, Inc. 10-Q 2025-11-12

   Item 4. Controls and Procedures

   material weakness in internal controls is a deficiency in internal control, or combination of control deficiencies, that adversely affects our ability
   3 matches in this document Show context Copy citation

5. APUS Apimeds Pharmaceuticals US, Inc. 10-Q 2025-08-19

   Item 4. Controls and Procedures

   material weakness in internal controls is a deficiency in internal control, or combination of control deficiencies, that adversely affects our ability
   3 matches in this document Show context Copy citation

6. APUS Apimeds Pharmaceuticals US, Inc. 10-Q 2026-08-14

   Item 4. Controls and Procedures

   material weaknesses in internal control over financial reporting relating to the lack of sufficient qualified accounting personnel, the absence of controls
   1 match in this document Show context Copy citation